Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
Jinal N. Bhiman, Simone I. Richardson, Bronwen E. Lambson, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 41

Showing 1-25 of 41 citing articles:

Tracking the COVID-19 vaccines: The global landscape
Tushar Yadav, Swatantra Kumar, Gourav Mishra, et al.
Human Vaccines & Immunotherapeutics (2023) Vol. 19, Iss. 1
Open Access | Times Cited: 48
An overview of the vaccine platforms to combat COVID-19 with a focus on the subunit vaccines
Fatemeh Bayani, Negin Safaei Hashkavaei, Sareh Arjmand, et al.
Progress in Biophysics and Molecular Biology (2023) Vol. 178, pp. 32-49
Open Access | Times Cited: 43
Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
Paul T. Heath, Eva Galiza, D. N. Baxter, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 3, pp. 398-407
Open Access | Times Cited: 53
Toward a pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses
Chang Yi Wang, Wen‐Jiun Peng, Be-Sheng Kuo, et al.
PLoS Pathogens (2023) Vol. 19, Iss. 4, pp. e1010870-e1010870
Open Access | Times Cited: 24
Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine
Eddie Underwood, Lisa M. Dunkle, Shabir A. Madhi, et al.
Expert Review of Vaccines (2023) Vol. 22, Iss. 1, pp. 501-517
Open Access | Times Cited: 24
What makes SARS‐CoV‐2 unique? Focusing on the spike protein
Jingbo Qian, Shi-Chang Zhang, Fang Wang, et al.
Cell Biology International (2024) Vol. 48, Iss. 4, pp. 404-430
Open Access | Times Cited: 12
Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines
Congrui Zhu, Shengmei Pang, Jiaqi Liu, et al.
Drugs (2024) Vol. 84, Iss. 4, pp. 403-423
Closed Access | Times Cited: 9
COVID-19 Variants and Vaccine Development
Ziyao Zhao, Sahra Bashiri, Zyta M. Ziora, et al.
Viruses (2024) Vol. 16, Iss. 5, pp. 757-757
Open Access | Times Cited: 5
Assessing the effectiveness of vaccination strategies against respiratory pathogens⁠
Mohammad Puad Abdullah, Faisal M. Alanazi, Saad F. Gandurah, et al.
International Journal of Community Medicine and Public Health (2025)
Open Access
Application of Traditional Vaccine Development Strategies to SARS-CoV-2
Halie M. Rando, Ronan Lordan, Alexandra Lee, et al.
mSystems (2023) Vol. 8, Iss. 2
Open Access | Times Cited: 14
Immunogenicity and efficacy of vaccine boosters against SARS-CoV-2 Omicron subvariant BA.5 in male Syrian hamsters
Rafael Rahal Guaragna Machado, Jordyn Walker, Dionna Scharton, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 14
An Immunological Review of SARS-CoV-2 Infection and Vaccine Serology: Innate and Adaptive Responses to mRNA, Adenovirus, Inactivated and Protein Subunit Vaccines
Suhaila A. Al-Sheboul, Brent Brown, Yasemin Shboul, et al.
Vaccines (2022) Vol. 11, Iss. 1, pp. 51-51
Open Access | Times Cited: 18
Prototype and BA.5 protein nanoparticle vaccines protect against Omicron BA.5 variant in Syrian hamsters
Traci L. Bricker, Astha Joshi, Nadia Soudani, et al.
Journal of Virology (2024) Vol. 98, Iss. 3
Open Access | Times Cited: 3
Immunogenicity and efficacy of XBB.1.5 rS vaccine against EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Adrianus C. M. Boon, Nadia Soudani, Traci L. Bricker, et al.
Research Square (Research Square) (2024)
Open Access | Times Cited: 3
Safety and immunogenicity of the NVX-CoV2373 vaccine as a booster in adults previously vaccinated with the BBIBP-CorV vaccine
Seth Toback, Anthony M. Marchese, Brandy Warren, et al.
Vaccine (2024) Vol. 42, Iss. 7, pp. 1777-1784
Open Access | Times Cited: 3
Risk of SARS-CoV-2 breakthrough infection following NVX-CoV2373 and BNT162b2 vaccinations in Korean Adults: A population-based observational study
Hee Kyoung Kim, Seon Kyeong Park, Seung‐Ah Choe, et al.
Vaccine (2024) Vol. 42, Iss. 7, pp. 1440-1444
Closed Access | Times Cited: 3
Innovative translational platforms for rapid developing clinical vaccines against COVID‐19 and other infectious disease
Ning Wang, Ting Wang
Biotechnology Journal (2024) Vol. 19, Iss. 2
Closed Access | Times Cited: 3
NVX-CoV2373 induces humoral and cellular immune responses that are functionally comparable to vector and mRNA-based vaccines
Franz Mai, Marcel Kordt, Wendy Bergmann‐Ewert, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 3
Validation of a Pseudovirus Neutralization Assay for Severe Acute Respiratory Syndrome Coronavirus 2: A High-Throughput Method for the Evaluation of Vaccine Immunogenicity
Zhaohui Cai, Raj Kalkeri, Mi Wang, et al.
Microorganisms (2024) Vol. 12, Iss. 6, pp. 1201-1201
Open Access | Times Cited: 3
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Nadia Soudani, Traci L. Bricker, Tamarand L. Darling, et al.
Journal of Virology (2024)
Open Access | Times Cited: 3
The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection
Dandan Tian, Wenjian Nie, Yanhong Sun, et al.
Vaccines (2022) Vol. 10, Iss. 10, pp. 1699-1699
Open Access | Times Cited: 17
Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens
Sitthichai Kanokudom, Jira Chansaenroj, Nungruthai Suntronwong, et al.
International Journal of Infectious Diseases (2022) Vol. 126, pp. 64-72
Open Access | Times Cited: 15
Efficacy and Safety of COVID-19 Vaccines—An Update
Eshani Sharma, Sraddha Revinipati, Saisha Bhandari, et al.
Diseases (2022) Vol. 10, Iss. 4, pp. 112-112
Open Access | Times Cited: 15
Safety and Immunogenicity of the NVX-CoV2373 Vaccine as a Booster in Adults Previously Vaccinated with the BBIBP-CorV Vaccine: An Interim Analysis
Seth Toback, Anthony M. Marchese, Brandy Warren, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 8
Preclinical evaluation of manufacturable SARS-CoV-2 spike virus-like particles produced in Chinese Hamster Ovary cells
Sergio P. Alpuche-Lazcano, Matthew Stuible, Bassel Akache, et al.
Communications Medicine (2023) Vol. 3, Iss. 1
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top